<DOC>
	<DOCNO>NCT02235688</DOCNO>
	<brief_summary>This Phase 1 study investigate safety activity aldoxorubicin plus gemcitabine Subjects solid tumor .</brief_summary>
	<brief_title>Study Investigate Safety Activity Aldoxorubicin Plus Gemcitabine Subjects With Metastatic Solid Tumors</brief_title>
	<detailed_description>An open-label Phase 1b study investigate preliminary safety activity aldoxorubicin plus gemcitabine subject metastatic solid tumor administer dos 170 , 250 350 mg/m2 intravenous infusion ( IVI ) Day 1 every 21 day plus 900 mg/m2 gemcitabine Days 1 8 every 21 day .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Age 1580 year , male female . 2 . Advanced , unresectable , metastatic solid tumor either relapse refractory treatment least 1 prior chemotherapy immunotherapy regimen standard approve therapy exist . 3 . Progressive disease ( PD ) &lt; 6 month prior enrollment . 4 . Capable provide informed consent comply trial procedure . 5 . ECOG PS 02 ( Appendix B ) . 6 . Life expectancy &gt; 12 week . 7 . Measurable tumor lesion accord RECIST 1.1 criterion . 8 . Women must able become pregnant ( eg postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . ( Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ) 9 . Males female partner ( ) childbearing potential must use 2 form effective contraception ( see Inclusion 8 plus condom vasectomy male ) last menstrual period female partner study treatment 6 month final dose study treatment . 10 . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . 11 . Geographic accessibility site ensures subject able keep studyrelated appointment . 1 . Prior exposure &gt; 5 cycle 375 mg/m2 either doxorubicin Doxil® . 2 . Chemotherapy , palliative surgery and/or radiation treatment le 30 day prior enrollment . 3 . Exposure investigational agent within 30 day enrollment . 4 . CNS metastases symptomatic . 5 . History malignancy except cure basal cell carcinoma , superficial bladder cancer carcinoma situ cervix unless document free cancer ≥5 year . 6 . Laboratory value : Screening serum creatinine &gt; 1.5×ULN , ALT &gt; 3×ULN , &gt; 5×ULN liver metastasis present , total bilirubin &gt; 3×ULN , ANC &lt; 1,500/mm3 , platelet concentration &lt; 100,000/mm3 , hematocrit level &lt; 25 % female &lt; 27 % male , coagulation test ( PT , PTT , INR ) &gt; 1.5×ULN , albumin &lt; 2.0 g/dL . 7 . Clinically evident CHF &gt; class II NYHA guideline ( Appendix D ) . 8 . Current serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V ( Appendix F ) . 9 . Baseline QTc &gt; 470 msec and/or previous history QT prolongation take medication . Concomitant use medication associate high incidence QT prolongation allow ( Appendix G ) . 10 . History sign active coronary artery disease without angina pectoris . 11 . Serious myocardial dysfunction define scintigraphically ( eg MUGA , myocardial scintigram ) ultrasound determine absolute LVEF &lt; 45 % predict . 12 . History HIV infection . 13 . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . 14 . Major surgery within 21 day prior enrollment . 15 . Substance abuse condition might interfere subject 's participation study evaluation study result . 16 . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>aldoxorubicin</keyword>
	<keyword>INNO-206</keyword>
	<keyword>solid tumor</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>phase 1</keyword>
</DOC>